Cargando…
Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings
Various studies have emphasized an immunodepression state observed at the tumour site. To reverse this defect and based upon animal studies, we initiated a phase I clinical trial of gene therapy in which various doses of xenogeneic monkey fibroblasts (Vero cells) genetically engineered to produce hu...
Autores principales: | Tartour, E, Mehtali, M, Sastre-Garau, X, Joyeux, I, Mathiot, C, Pleau, J M, Squiban, P, Rochlitz, C, Courtney, M, Jantscheff, P, Herrmann, R, Pouillart, P, Fridman, W H, Dorval, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363414/ https://www.ncbi.nlm.nih.gov/pubmed/11076653 http://dx.doi.org/10.1054/bjoc.2000.1492 |
Ejemplares similares
-
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
por: Tartour, E., et al.
Publicado: (1994) -
XENOGENIZATION OF TUMOR CELLS BY TRANSFECTION WITH PLASMID CONTAINING env GENE OF FRIEND LEUKEMIA VIRUS
por: Sugiura, Chihiro, et al.
Publicado: (1988) -
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
por: Yuan, Jianda, et al.
Publicado: (2013) -
Xenogeneic stem cell transplantation: Research progress and clinical prospects
por: Jiang, Lin-Li, et al.
Publicado: (2021) -
Xenogenic Adenoviral Vectors
por: Mittal, Suresh K., et al.
Publicado: (2016)